Pipeline
Our Pipeline
TScan is leveraging its proprietary platform technologies to develop a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer.
PRODUCT DEVELOPMENT PIPELINE
(Target)
Hematologic Malignancies
(HA-1)
(HA-2)
(CD45)
(Target)
Solid Tumors (T-Plex)
(HPV16)
(MAGE-C2)
(MAGE-A4)
(PRAME)
(MAGE-A1)
(Target)
Autoimmunity
TSC-100 and TSC-101 are T cell receptor (TCR)-engineered T cell (TCR-T) therapy candidates in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse following allogeneic bone marrow transplantation (hematopoietic cell transplantation or HCT) (the ALLOHA™ trial, NCT05473910). More information about our ongoing clinical trial can be found here.
We are also developing multiplex TCR-T therapy candidates for the treatment of various solid tumors. Our goal is to build and expand the ImmunoBank, a repository of therapeutic TCRs that recognize diverse targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors (the PLEXI-T™ trial, NCT05973487). More information about our ongoing clinical trial can be found here.
In addition, we are applying our platform to identify targets and TCRs in autoimmune disorders.